GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: May 20, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | May 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-transaction
TL;DR
GSK is buying back its own stock via Citigroup.
AI Summary
GSK plc announced on May 20, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for publicly traded companies.
Key Players & Entities
- GSK plc (company) — The company making the share repurchase.
- Citigroup Global Markets Limited (company) — The corporate stockbroker acting on behalf of GSK plc.
- May 20, 2025 (date) — The date of the announcement and the transactions.
FAQ
What was the specific number of GSK plc ordinary shares purchased?
The filing states that a 'number' of ordinary shares were purchased, but does not specify the exact quantity.
What was the total dollar amount spent on the share repurchases?
The filing does not disclose the total dollar amount of the share repurchases.
Through which broker did GSK plc conduct these share repurchases?
GSK plc acted through its corporate stockbroker, Citigroup Global Markets Limited.
What is the par value of GSK plc's ordinary shares?
The ordinary shares are of 31¼ pence each.
Is this filing related to GSK's annual report?
No, this is a Form 6-K, which is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, and GSK indicates it files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 20, 2025 regarding GSK plc (GLAXF).